The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Abstract
The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge. Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of an associated risk of agranulocytosis. This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics. DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks. Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks. Two hundred sixty-eight patients were entered in the double-blind comparison. When a priori criteria were used, 30% of the clozapine-treated patients were categorized as responders compared with 4% of chlorpromazine-treated patients. Clozapine produced significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas. Although no cases of agranulocytosis occurred during this relatively brief study, in our view, the apparently increased comparative risk requires that the use of clozapine be limited to selected treatment-resistant patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the only drug that has been licensed as monotherapy for a treatment resistant condition in psychiatry is clozapine for TRS, which gained regulatory approval on the basis of 2 studies. 12, 79”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [12]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.12.1518 · Cited by 541
Honigfeld, G., & Klett, C. J. (1965) · Journal of Clinical Psychology · doi:10.1002/1097-4679(196501)21:1<65::aid-jclp2270210122>3.0.co;2-i · Cited by 435
Controversy in Counting and Attributing Events in Clinical Trials
Sackett, D. L., & Gent, M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197912273012602 · Cited by 413
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
Important Issues in the Drug Treatment of Schizophrenia
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 284
Povlsen, U. J., Norrng, U., Fog, R., & Gerlach, J. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb01268.x · Cited by 278
Clozapine-induced agranulocytosis: A genetic and epidemiologic study
de la Chapelle, A., Kari, C., Nurminen, M., & Hernberg, S. (1977) · Human Genetics · doi:10.1007/bf00393581 · Cited by 211
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Metadata
- Authors
- Kane, J.
- Affiliations
- Long Island Jewish Medical Center (US)
- Corresponding author
- Kane, John
- ORCID
- Kane, John
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1988-09-01
- Volume
- 45
- Issue
- 9
- Pages
- 789
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2085360366
- Cited by
- 4,156
- References
- 21
- Citations by year
- 2026: 76 · 2025: 89 · 2024: 95 · 2023: 91 · 2022: 89 · 2021: 101 · 2020: 91 · 2019: 104 · 2018: 90 · 2017: 89 · 2016: 114 · 2015: 116 · 2014: 107 · 2013: 95 · 2012: 115
- FWCI
- 57.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH41960, MH 47808, MH41954)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- clozapine, treatment-resistant schizophrenia, atypical antipsychotics, chlorpromazine, haloperidol, agranulocytosis, antipsychotic efficacy, negative symptoms, adverse drug reactions
- MeSH terms
- Adult, Chlorpromazine, Clinical Trials as Topic, Clozapine, Dibenzazepines, Double-Blind Method, Female, Haloperidol, Humans, Male, Middle Aged, Random Allocation, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine. https://app.cochat.ai/papers/10.1001/archpsyc.1988.01800330013001
- The paper
- Kane, J. (1988). Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800330013001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.